European Commission has approved Keytruda in combination with carboplatin and either paclitaxel or nab-paclitaxel, for the first-line treatment of adults with metastatic squamous non-small cell lung cancer.
The Biden administration has left NIH in a weakened state, intensifying politicization of science on Capitol Hill and eroding the bipartisan support the government’s premier biomedical research agency has traditionally enjoyed.
